In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™)

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 1001-1008

  Canta, A ^a   Chiorazzi, A ^a   Carozzi, V ^a   Meregalli, C ^a   Oggioni, N ^a   Sala, B ^a   Crippa, L ^b   Avezza, F ^a   Forestieri, D ^c   Rotella, G ^c   Zucchetti, M ^c   Cavaletti, G ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTOVET   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cisplatin; Lipoplatin ; Liposomes; Nerve conduction velocity; Peripheral neurotoxicity; Wistar rats

Indexed keywords

CISPLATIN; LIPOPLATIN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG TISSUE LEVEL; FEMALE; IN VIVO STUDY; KIDNEY FAILURE; NEPHROTOXICITY; NERVE CONDUCTION; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SPINAL GANGLION; TOXICITY TESTING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; NEUROTOXICITY SYNDROMES; RATS; RATS, WISTAR; TOXICITY TESTS;

EID: 80054743466     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1574-3     Document Type: Article

References (38)

1. B Rosenberg L Vancamp T Krigas 1965 Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode Nature 205 698 699 14287410 10.1038/205698a0 1:CAS:528:DyaF2MXns1aruw%3D%3D
2. B Rosenberg L Vancamp JE Trosko VH Mansour 1969 Platinum compounds: a new class of potent antitumour agents Nature 222 385 386 5782119 10.1038/222385a0 1:CAS:528:DyaF1MXktVWquro%3D
3. B Rosenberg 1973 Platinum coordination complexes in cancer chemotherapy Naturwissenschaften 60 399 406 4203933 10.1007/BF00623551 1:CAS:528: DyaE2cXjtlKmsg%3D%3D
4. LM Hess M Benham-Hutchins TJ Herzog CH Hsu DC Malone GH Skrepnek MK Slack DS Alberts 2007 A meta-analysis of the efficacy of intraperitoneal CDDP for the front-line treatment of ovarian cancer Int J Gynecol Cancer 17 561 570 17504373 10.1111/j.1525-1438.2006.00846.x 1:STN:280:DC%2BD2s3ptlKhsg%3D%3D (Pubitemid 46744010)
5. SR McWhinney RM Goldberg HL McLeod 2009 Platinum neurotoxicity pharmacogenetics Mol Cancer Ther 8 10 16 19139108 10.1158/1535-7163.MCT-08-0840 1:CAS:528:DC%2BD1MXjvFSntQ%3D%3D
6. K Pliarchopoulou D Pectasides 2010 Late complications of chemotherapy in testicular cancer Cancer Treat Rev 36 262 267 20092952 10.1016/j.ctrv.2009.12. 011 1:CAS:528:DC%2BC3cXksFChtrk%3D
7. B Rosenberg 1977 Noble metal complexes in cancer chemotherapy Adv Exp Med Biol 91 129 150 343531 1:STN:280:DyaE1c7itVOitg%3D%3D
8. JM Hill RJ Speer 1982 Organo-platinum complexes as antitumor agents Antic Res 2 173 186 1:STN:280:DyaL3s%2FitFWhtg%3D%3D
9. Lippert B (1999) CDDP: Chemistry and biochemistry of a leading anticancer drug. Wiley-VCH, New York
10. E Wong CM Giandomenico 1999 Current status of platinum based antitumor drugs Chem Rev 99 2451 2466 11749486 10.1021/cr980420v 1:CAS:528: DyaK1MXltFSrsrc%3D
11. GL Clayman LK Dreiling 1999 Injectable modalities as local and regional strategies for head and neck cancer Hematol Oncol Clin North Am 13 787 810 10494514 10.1016/S0889-8588(05)70093-9 1:STN:280:DyaK1MvisVejsw%3D%3D (Pubitemid 29407114)
12. T Boulikas M Vougiouka 2004 Recent clinical trials using CDDP, carboplatin and their combination chemotherapy drugs Oncol Rep 11 559 595 14767508 1:CAS:528:DC%2BD2cXitVartLs%3D
13. A Ardizzoni L Boni M Tiseo FV Fossella JH Schiller M Paesmans D Radosavljevic A Paccagnella P Zatloukal P Mazzanti D Bisset R Rosell 2007 CDDP- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis J Natl Cancer Inst 99 847 857 17551145 10.1093/jnci/djk196 1:CAS:528: DC%2BD2sXns1als7s%3D
14. FP Harmers WH Gispen JP Neijt 1991 Neurotoxic side-effects of CDDP Eur J Cancer 27 372 376 1827334 10.1016/0277-5379(91)90549-S 1:STN:280: DyaK3M3it1Kruw%3D%3D
15. G Cavaletti G Tredici 1995 CDDP neuropathy Neurology 45 596 7898730 1:STN:280:DyaK2M3gs1Gmuw%3D%3D
16. HD Humes 1999 Insights into ototoxicity. Analogies to nephrotoxicity Ann N Y Acad Sci 884 15 18 10842580 1:CAS:528:DC%2BD3cXhsV2itw%3D%3D
17. M Al-Sarraf 1987 Chemotherapeutic management of head and neck cancer Cancer Metastasis Rev 6 181 198 3319271 10.1007/BF00144263 1:STN:280: DyaL1c%2FotVOrtg%3D%3D
18. JM Hill RJ Speer 1982 Organo-platinum complexes as antitumor agents Anticancer Res 2 173 186 6751211 1:STN:280:DyaL3s%2FitFWhtg%3D%3D
19. G Cavaletti L Marzorati G Bogliun N Colombo M Marzola MR Pittelli G Tredici 1992 CDDP-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity Cancer 69 203 207 1309303 10.1002/1097-0142(19920101)69:1<203::AID-CNCR2820690133>3.0.CO;2-1 1:STN:280:DyaK38%2FovFynsQ%3D%3D
20. P Devarajan R Tarabishi J Mishra Q Ma A Kourvetaris M Vougiouka T Boulikas 2004 Low renal toxicity of LipoplatinTM compared to CDDP in animals Anticancer Res 24 2193 2200 15330160 1:CAS:528:DC%2BD2cXot1Cgtb4%3D (Pubitemid 39166294)
21. CF Jehn T Boulikas A Kourvetaris G Kofla K Possinger D Lüftner 2009 First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) Anticancer Res 28 3961 3964
22. C Meregalli A Canta VA Carozzi A Chiorazzi N Oggioni A Gilardini C Ceresa F Avezza L Crippa P Marmiroli G Cavaletti 2010 Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats Eur J Pain 14 343 350 19695912 10.1016/j.ejpain.2009.07.001 1:CAS:528:DC%2BC3cXktlCrtrw%3D
23. G Cavaletti E Cavalletti P Montaguti N Oggioni O De Negri G Tredici 1997 Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat Neurotoxicology 18 137 145 9215996 1:CAS:528:DyaK2sXkslahsLg%3D
24. G Cavaletti D Fabbrica C Minoia L Frattola G Tredici 1998 Carboplatin toxic effects on the peripheral nervous system of the rat Ann Oncol 9 443 447 9636837 10.1023/A:1008231925889 1:STN:280:DyaK1czgtVCltA%3D%3D (Pubitemid 28273039)
25. A Canta C Meregalli A Chiorazzi VA Carozzi L Crippa P Marmiroli G Cavaletti 2010 The ventral caudal nerve: a physiologic-morphometric study in three different rat strains J Peripher Nerv Syst 15 140 146 20626777 10.1111/j.1529-8027.2010.00261.x
26. G Cavaletti G Tredici P Marmiroli MG Petruccioli I Barajon D Fabbrica 1992 Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic CDDP (DDP) administration in rats Acta Neuropathol 84 364 371 1441917 10.1007/BF00227662 1:CAS:528:DyaK3sXjt1KnsA%3D%3D
27. V Carozzi A Chiorazzi A Canta N Oggioni A Gilardini V Rodriguez-Menendez F Avezza L Crippa C Ceresa G Nicolini M Bossi G Cavaletti 2009 Effect of the chronic combined administration of CDDP and paclitaxel in a rat model of peripheral neurotoxicity Eur J Cancer 45 656 665 19091544 10.1016/j.ejca.2008. 10.038 1:CAS:528:DC%2BD1MXitF2gt7o%3D
28. Arany I, Safirstein RL (2003) CDDP nephrotoxicity. Semin Nephrol 23:460-464
29. L Kelland 2007 The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 7 573 584 17625587 10.1038/nrc2167 1:CAS:528:DC%2BD2sXotVKru7c%3D (Pubitemid 47106628)
30. Cavaletti G (2008) Peripheral neurotoxicity of platinum-based chemotherapy. Nat Rev Cancer 8(1):1p following 71; author reply 1p following 71
31. T Boulikas M Vougiouka 2003 CDDP and platinum drugs at the molecular level Oncol Rep 10 1663 1682 14534679 1:CAS:528:DC%2BD3sXptlCktLw%3D
32. MI Koukourakis A Giatromanolaki M Pitiakoudis G Kouklakis P Tsoutsou I Abatzoglou M Panteliadou K Sismanidou E Sivridis T Boulikas 2010 Concurrent Liposomal CDDP (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a Phase I/II Study Int J Radiat Oncol Biol Phys 78 150 155 20138443 10.1016/j.ijrobp.2009.07.1733 1:CAS:528: DC%2BC3cXhtVaqsbfF
33. T Boulikas 2007 Molecular mechanism of CDDP and its liposomally incapsulated form, LipoplatinTM. LipoplatinTM as a chemotherapy and antiangiogenesis drug Cancer Therapy 5 349 376
34. T Boulikas 2009 Clinical overview on Lipoplatin: a successful liposomal formulation of CDDP Expert Opin Investig Drugs 18 1197 1218 19604121 10.1517/13543780903114168 1:CAS:528:DC%2BD1MXosFCmtb4%3D
35. V Levresse L Marek D Blumberg LE Heasley 2002 Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells Mol Pharmacol 62 689 697 12181446 10.1124/mol.62.3.689 1:CAS:528:DC%2BD38XmsVKmu70%3D (Pubitemid 36329388)
36. Stathopoulos GP, Boulikas T, Rigatos SK (2002) Liposomal CDDP combined with gemcitabine in pretreated advanced cancer patients. Phase I-II study. Ann Oncol 13:25
37. T Boulikas 2004 Low toxicity and anticancer activity of a novel liposomal CDDP (LipoplatinTM) in mouse xenografts Oncol Rep 12 3 12 15201951 1:CAS:528:DC%2BD2cXlvVerurc%3D
38. N Mylonakis A Athanasiou N Ziras J Angel A Rapti S Lampaki N Politis C Karanikas C Kosmas 2010 Phase II study of liposomal CDDP (LipoplatinTM) plus gemcitabine versus CDDP plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer Lung Cancer 68 240 247 19628292 10.1016/j.lungcan.2009.06.017 1:STN:280:DC%2BC3c3itFanuw%3D%3D